MedTrace Logo

A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies

NCT00720278 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 526

Last updated 2010-03-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to determine if two allergy medications are more effective than placebo.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

DRUG

0.15% azelastine hydrochloride 1644 mcg daily

0.15% azelastine hydrochloride 1644 mcg daily

DRUG

0.1% azelastine hydrochloride 1096 mcg daily

0.1% azelastine hydrochloride 1096 mcg daily

DRUG

Placebo

0 mcg Placebo daily

Sponsors & Collaborators

  • Meda Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2007-10-31
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00720278 on ClinicalTrials.gov